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Some 20 years ago1, an enzyme complex was linked to the dramatic changes in development that occur when seedlings 
push through the soil and encounter sunlight. 
This complex, named the COP9 signalosome 
(CSN), is now thought to be common to all 
animals, plants and fungi. The CSN is involved 
in protein degradation, but because of its com-
plicated structure, detailed knowledge of how 
its activity is controlled has remained elusive. 
In a paper published on Nature’s website today, 
Lingaraju et al.2 report the crystallization of the 
CSN and determine its structure to a resolu-
tion of a remarkable 3.8 ångströms. 
The CSN consists of eight 
protein subunits, CSN1–8, and 
regulates a family of enzyme com-
plexes called cullin–RING E3 
ubiquitin ligases (CRLs)3, which 
modify their target proteins by 
attaching ubiquitin proteins to 
them. Ubiquitin modifications can 
have many effects on proteins, from 
influencing their cellular location 
to causing their degradation. In 
fact, the cullin protein that makes 
up the backbone of each CRL must 
itself be modified by a ubiquitin-
like protein, NEDD8, before it 
can function as a ubiquitin ligase. 
The CSN inhibits this activity by 
detaching NEDD8 from cullin, and 
can also bind ‘deneddylated’ CRLs, 
thereby maintaining CRL inactivity 
after NEDD8 removal4–7.
The CSN structure described by 
Lingaraju and colleagues brings 
to mind a widely splayed hand 
on which a small box sits askew, 
topped by a tomato (Fig. 1). Like 
a hand, the CSN has five digits 
(the amino-terminal ends of 
CSN1, 2, 4, 7, and 3 plus 8) pro-
jecting from an organizing centre, 
the palm. The palm is formed by 
the ‘winged-helix’ subdomains 
of these subunits, which associate to form 
a horseshoe-shaped structure. Resting on 
the hand is the box, formed by bundling of 
the carboxy-terminal ends of each subunit. 
Sitting atop this platform is the CSN5–CSN6 
tomato. 
Whereas some aspects of the CSN structure 
were anticipated from previous work on 
related proteins, it is a big surprise that the 
structure obtained by Lingaraju and co-
workers is in an inactive configuration. The 
active site of the CSN is specified by a ‘JAMM’ 
domain in the CSN5 subunit. Typically, the 
active sites of the enzymes in the JAMM family 
contain a zinc ion (Zn2+) bound by three 
evolutionarily conserved amino-acid residues 
(two histidines and an aspartate), with the 
remaining ligand-binding site of Zn2+occupied 
by a water molecule that has been activated by 
another evolutionarily conserved amino acid, 
glutamate 76 (Glu 76; ref. 8). This activated 
water molecule detaches ubiquitin or ubiqui-
tin-like proteins from their targets by hydrol-
ysis. Whereas the histidine and aspartate 
residues of CSN5 are positioned as expected 
in the CSN structure, the water molecule is 
replaced by another amino acid, Glu 104. This 
explains a long-standing puzzle: whereas other 
JAMM-containing proteins efficiently cleave 
model substrates, such as ubiquitin with a 
rhodamine dye attached to its C terminus, 
purified CSN does so only poorly.
Lingaraju et al. tested the role of Glu 104 
in CSN regulation by performing enzyme 
assays on CSN complexes in which Glu 104 
was mutated. This mutant cleaved ubiquitin– 
rhodamine much faster than the natural 
enzyme, indicating that Glu104–Zn2+ bind-
ing might keep the CSN in an inactive state 
when it is free from CRL. Notably, mutation 
of the adjacent residue, threonine 103, results 
in defective development of the nervous sys-
tem in fruit flies9, which suggests that Glu 104- 
mediated regulation is required for proper 
control of CSN activity in vivo. 
The inhibited state of unbound 
CSN raises the obvious question of 
how the CSN gains its activity on 
binding CRLs. The authors used 
computer-modelling studies to 
compare their crystal structure of 
free CSN with a structure deter-
mined by electron micro scopy7 
in which the CSN was bound to a 
CRL enzyme to which NEDD8 is 
attached. This comparison showed 
clearly that, to reconcile the two 
structures, substantial rearrange-
ments of CSN2, CSN4 and CSN5–
CSN6 must occur when the CSN 
and CRL bind (Fig. 1). In particu-
lar, movements in CSN4 and CSN6 
must lead to a change in the CSN4–
CSN6 interface. 
To probe the significance of 
this interface, Lingaraju and col-
leagues deleted a β-hairpin loop in 
CSN6 that contributes to its inter-
action with CSN4. Surprisingly, 
the resulting complex, like the 
Glu 104 mutant, efficiently cleaved 
ubiquitin–rhodamine. It also 
deneddylated CRL more than four 
times faster than did the wild-type 
enzyme. These observations make it 
tempting to speculate that CSN4 is 
the signalosome’s CRL sensor, and 
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Figure 1 | Structure of the COP9 signalosome (CSN). This enzyme 
complex is comprised of eight CSN protein subunits. Six subunits make 
up the base of the CSN, a splayed ‘hand’ in which the proteins’ N-terminal 
ends are at the fingertips and their winged-helix domains, drawn as circles, 
assemble to form the palm (partially obscured). The C-terminal ends of each 
protein are bundled together into a ‘box’ that sits askew on the hand. The 
CSN5 and CSN6 subunits associate intimately to form a ‘tomato’ sitting on 
the box. Lingaraju et al.2 report that the CSN is inactive until it binds to its 
target, a cullin–RING E3 ubiquitin-ligase enzyme complex. On binding, the 
CSN undergoes activating conformational changes, indicated by coloured 
arrows that represent the movements of the altered subunits. For simplicity, 
the box is drawn as a uniform bundle, and so does not represent the actual 
position and length of each C terminus. (Figure adapted from Fig. 1 of ref. 2.) 
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that CSN4 movement during CRL binding 
triggers a cascade of rearrangements transmit-
ted through CSN6 that prise CSN5’s Glu 104 
residue away from Zn2+, so that Glu 76 can 
move into position, activating the CSN. How-
ever, when the authors made a double mutant 
lacking both the CSN6 loop and Glu 104, they 
found it to be more active than either individual 
mutant, suggesting that these two mutations 
have independent effects, rather than acting in 
a linear cascade. Furthermore, the N-terminal 
region of CSN4 does not seem to make strong 
contact with CRL7, indicating that the CSN’s 
CRL sensor may be in another subunit. 
This study highlights a crucial lesson on the 
use of evolutionary conservation to predict 
enzyme regulation. Comparing the crystal 
structure of the CSN with those of the JAMM-
containing enzymes AMSH-LP (ref. 10) and 
Rpn11 (refs 11, 12) reveals that, although all 
three use the same amino acids to coordinate 
Zn2+ and the activated water molecule, their 
activities are controlled in markedly different 
ways. AMSH-LP seems to be constitutively 
active, Rpn11 activity is promoted by rear-
rangements that bring the enzyme and its 
target substrate into proximity13,14, and CSN5 
is activated by substrate-driven relief of inhibi-
tion. Strikingly, CSN5 is inhibited by distinct 
mechanisms depending on whether the subu-
nit is on its own15 or integrated into the CSN. 
Although some generalizations apply across 
the JAMM family, it is clear that each member 
has its own distinctive features.
What lies ahead for research on the CSN? 
It will be fascinating to examine the structure 
of different CSN mutants, to work out the 
mechanism by which binding to CRLs brings 
about major conformational changes. It would 
also be wonderful to see a CSN–NEDD8–CRL 
complex in its full glory, to gain an atomic-
level view of the CSN–CRL interface and how 
it might be influenced by NEDD8 or sub-
strates that bind to CRL. Another question is 
whether binding of the CSN to neddylated or 
de neddylated CRL promotes the same confor-
mational change in the CSN. 
Binding and kinetic studies of the CSN and 
the mutated complexes reported by Lingaraju 
et al. should reveal whether the CSN’s cata-
lytic rate is determined by the conformational 
rearrangement that occurs on CRL binding. 
Furthermore, in vivo studies with Glu 104 and 
CSN6-loop mutants should show why free 
CSN must be inhibited.
Finally, this structure may help the design 
of drugs that act on the CSN, which could be 
an attractive target for the treatment of breast 
and liver cancer16,17. Although detailed char-
acterization of CSN inhibitors has not been 
reported, my laboratory has identified several 
candidates through high-throughput screen-
ing (PubChem AID652009). The surpris-
ing observations reported by Lingaraju et al. 
suggest that it may be possible to inhibit the 
CSN but spare other JAMM proteins, by inter-
fering with the active-site rearrangement that 
occurs when the CSN and CRL bind. ■
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